Nasus Pharma is trading 5.82% down at $3.05, with the immediate reason unclear.

  • No new August 13, 2026 company announcement, filing, analyst action, or other clear catalyst was identified in available coverage.
  • The latest prominent company news was the July 28 appointment of Brendan P. O’Grady as chief executive, which predates the decline.
  • Broader U.S. indexes are moving higher.